(INSM) Insmed - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 23.028m USD | Total Return: 60.1% in 12m
Avg Turnover: 321M
Qual. Beats: 0
Rev. Trend: 91.1%
Qual. Beats: 0
Warnings
Share dilution 19.1% YoY
Interest Coverage Ratio -14.3 is critical
Altman Z'' -13.61 < 1.0 - financial distress zone
Below Avwap Earnings
Tailwinds
No distinct edge detected
Insmed Incorporated is a global biopharmaceutical company focused on developing and commercializing therapies for rare and serious diseases, primarily within the respiratory and orphan disease sectors. The company currently markets ARIKAYCE for refractory nontuberculous mycobacterial (NTM) lung infections and maintains a late-stage pipeline including brensocatib for bronchiectasis and treprostinil palmitil for pulmonary hypertension. Its research expansion includes gene therapy platforms targeting Duchenne muscular dystrophy and amyotrophic lateral sclerosis.
The biotechnology sector typically requires high research and development (R&D) expenditure, as companies must navigate multi-phase clinical trials and stringent regulatory approvals before achieving commercial scale. Insmed utilizes a specialized commercialization model that targets niche patient populations with high unmet medical needs, often benefiting from orphan drug designations which provide market exclusivity periods.
For a more comprehensive look at these pipeline developments, ValueRay offers additional data points.
- ARIKAYCE commercial expansion drives core revenue growth in global refractory lung markets
- Brensocatib Phase 3 clinical outcomes determine long-term valuation in bronchiectasis treatment
- Treprostinil palmitil regulatory approvals impact entry into pulmonary hypertension markets
- High research and development expenditures necessitate future capital raises or partnerships
- Gene therapy pipeline advancement influences speculative premium and long-term asset diversification
| Net Income: -1.18b TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.51 > 0.02 and ΔFCF/TA -0.43 > 1.0 |
| NWC/Revenue: 152.8% < 20% (prev 305.3%; Δ -152.6% < -1%) |
| CFO/TA -0.43 > 3% & CFO -895.7m > Net Income -1.18b |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 4.47 > 1.5 & < 3 |
| Outstanding Shares: last quarter (215.5m) vs 12m ago 19.14% < -2% |
| Gross Margin: 81.56% > 18% (prev 0.76%; Δ 8.08k% > 0.5%) |
| Asset Turnover: 42.26% > 50% (prev 21.14%; Δ 21.12% > 0%) |
| Interest Coverage Ratio: -14.31 > 6 (EBITDA TTM -1.14b / Interest Expense TTM 80.9m) |
| A: 0.60 (Total Current Assets 1.61b - Total Current Liabilities 361.0m) / Total Assets 2.08b |
| B: -2.79 (Retained Earnings -5.80b / Total Assets 2.08b) |
| C: -0.60 (EBIT TTM -1.16b / Avg Total Assets 1.94b) |
| D: -4.23 (Book Value of Equity -5.80b / Total Liabilities 1.37b) |
| Altman-Z'' = -13.61 = D |
| DSRI: 1.74 (Receivables 178.6m/47.7m, Revenue 819.6m/381.0m) |
| GMI: 0.94 (GM 81.56% / 76.49%) |
| AQI: 1.01 (AQ_t 0.16 / AQ_t-1 0.16) |
| SGI: 2.15 (Revenue 819.6m / 381.0m) |
| TATA: -0.14 (NI -1.18b - CFO -895.7m) / TA 2.08b) |
| Beneish M = -1.78 (Cap -4..+1) = B |
As of May 27, 2026, the stock is trading at USD 108.87 with a total of 2,273,613 shares traded.
Over the past week, the price has changed by +1.61%,
over one month by -19.94%,
over three months by -27.42% and
over the past year by +60.06%.
Insmed has received a consensus analysts rating of 4.81. Therefore, it is recommended to buy INSM.
- StrongBuy: 17
- Buy: 4
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 200 | 83.7% |
P/E Forward = 16.3666
P/S = 28.0976
P/B = 33.6806
P/EG = 1.0916
Revenue TTM = 819.6m USD
EBIT TTM = -1.16b USD
EBITDA TTM = -1.14b USD
Long Term Debt = 542.2m USD (from longTermDebt, last quarter)
Short Term Debt = 14.4m USD (from shortTermDebt, last quarter)
Debt = 786.5m USD (from shortLongTermDebtTotal, last quarter) + Leases 38.1m
Net Debt = -437.0m USD (calculated: Debt 786.5m - CCE 1.22b)
Enterprise Value = 22.6b USD (23.0b + Debt 786.5m - CCE 1.22b)
Interest Coverage Ratio = -14.31 (Ebit TTM -1.16b / Interest Expense TTM 80.9m)
EV/FCF = -21.27x (Enterprise Value 22.6b / FCF TTM -1.06b)
FCF Yield = -4.70% (FCF TTM -1.06b / Enterprise Value 22.6b)
FCF Margin = -129.6% (FCF TTM -1.06b / Revenue TTM 819.6m)
Net Margin = -144.4% (Net Income TTM -1.18b / Revenue TTM 819.6m)
Gross Margin = 81.56% ((Revenue TTM 819.6m - Cost of Revenue TTM 151.2m) / Revenue TTM)
Gross Margin QoQ = 83.82% (prev 83.24%)
Tobins Q-Ratio = 10.88 (Enterprise Value 22.6b / Total Assets 2.08b)
Interest Expense / Debt = 10.29% (Interest Expense 80.9m / Debt 786.5m)
Taxrate = 21.0% (US default 21%)
NOPAT = -915.2m (EBIT -1.16b * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.71 (Total Current Assets 1.61b / Total Current Liabilities 434.4m)
Debt / Equity = 1.12 (Debt 786.5m / totalStockholderEquity, last quarter 704.9m)
Debt / EBITDA = 0.38 (negative EBITDA) (Net Debt -437.0m / EBITDA -1.14b)
Debt / FCF = 0.41 (negative FCF - burning cash) (Net Debt -437.0m / FCF TTM -1.06b)
Total Stockholder Equity = 909.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -61.04% (Net Income -1.18b / Total Assets 2.08b)
RoE = -17.64% (Net Income TTM -1.18b / Total Stockholder Equity 6.71b)
RoCE = -15.97% (EBIT -1.16b / Capital Employed (Equity 6.71b + L.T.Debt 542.2m))
RoIC = -53.19% (negative operating profit) (NOPAT -915.2m / Invested Capital 1.72b)
WACC = 7.32% (E(23.0b)/V(23.8b) * Re(7.29%) + D(786.5m)/V(23.8b) * Rd(10.29%) * (1-Tc(0.21)))
Discount Rate = 7.29% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 100.00 | Cagr: 19.32%
[DCF] Fair Price = unknown (Cash Flow -1.06b)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.64 | # QB: 0
Revenue Correlation: 91.13 | Revenue CAGR: 38.91% | SUE: 0.56 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.77 | Chg30d=+1.56% | Revisions=-14% | Analysts=13
EPS next Quarter (2026-09-30): EPS=-0.60 | Chg30d=-3.30% | Revisions=-20% | Analysts=13
EPS current Year (2026-12-31): EPS=-2.74 | Chg30d=+1.88% | Revisions=-18% | GrowthEPS=+57.3% | GrowthRev=+180.3%
EPS next Year (2027-12-31): EPS=0.40 | Chg30d=-46.03% | Revisions=-41% | GrowthEPS=+114.7% | GrowthRev=+64.8%
[Analyst] Revisions Ratio: -41%